Using machine learning to identify high-risk patients with early-stage lung cancer
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
This study is trying to see if machine learning can help find patients with early-stage lung cancer who are more likely to have their cancer come back after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT05732974 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify patients with resected non-small cell lung cancer (NSCLC) Stage IIIA who are at high risk of relapse using a machine learning approach. It will utilize data from an existing cohort of patients enrolled in a previous study as a training set, alongside a new concurrent cohort for validation. The goal is to develop a predictive model that can help in stratifying patients based on their risk of cancer recurrence, addressing the current lack of validated prognostic biomarkers in this area.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with early-stage non-small cell lung cancer who are scheduled for surgical resection.
Not a fit: Patients with other cancers in the last five years or those under legal protection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk stratification for patients, allowing for more personalized treatment plans and potentially better outcomes.
How similar studies have performed: While machine learning approaches in oncology are gaining traction, this specific application in identifying relapse risk in NSCLC is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with an early stage of non small cell lung cancer * Indication of surgical resection * Patient able to understand and give his consent * Patient affiliated to the health insurance Exclusion Criteria: * Patient with another cancer in the last 5 years * Patient with an allergy to the contrast medium * Patient under legal protection
Where this trial is running
Toulouse
- Julien MAZIERES — Toulouse, France (Recruiting)
Study contacts
- Principal investigator: Julien MAZIERES, MD, PhD — University Hospital, Toulouse
- Study coordinator: Julien MAZIERES, MD, PhD
- Email: mazieres.j@chu-toulouse.fr
- Phone: 0567771837
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.